Table 3 The effect of L-NMMA on GFR and renal handling of sodium and potassium after six weeks of paricalcitol treatment in patients with stage III-IV CKD and albuminuria (n = 21)
Baseline | 30 min | 60 min | 90 min | 120 min | P Within | P Between | |
|---|---|---|---|---|---|---|---|
GFR ( 51 Cr-EDTA clearance) | |||||||
Placebo | 26.3 ± 13.3 | 22.8 ± 10.9 | 24.2 ± 11.1 | 26.0 ± 11.7 | 27.8 ± 11.5 | 0.68 | 0.31 |
Paricalcitol | 23.6 ± 11.5* | 20.3 ± 9.7 | 22.5 ± 10.9 | 22.5 ± 12.0 | 23.9 ± 12.8 | 0.89 | |
Urine output (ml/min) | |||||||
Placebo | 4.5 ± 2.1 | 3.1 ± 1.3 | 3.4 ± 1.2 | 3.6 ± 1.1 | 4.0 ± 1.8 | 0.02 | 0.15 |
Paricalcitol | 3.4 ± 1.5* | 2.4 ± 0.9 | 2.8 ± 1.2 | 3.1 ± 1.1 | 3.7 ± 1.5 | 0.01 | |
Free water clearance (ml/min) | |||||||
Placebo | 1.7 ± 1.7 | 1.6 ± 1.4 | 1.1 ± 0.9 | 1.3 ± 0.9 | 1.5 ± 1.0 | 0.65 | 0.16 |
Paricalcitol | 0.8 ± 1.0* | 0.8 ± 1.0 | 0.7 ± 0.7 | 1.0 ± 0.9 | 1.3 ± 0.9 | 0.27 | |
FE Na (%) | |||||||
Placebo | 5.9 ± 4.3 | 4.7 ± 3.4 | 4.4 ± 3.1 | 4.2 ± 2.8 | 4.1 ± 2.7 | 0.37 | 0.54 |
Paricalcitol | 5.9 ± 4.5 | 4.4 ± 3.7 | 4.4 ± 3.4 | 4.6 ± 4.1 | 4.6 ± 4.0 | 0.73 | |
FE K (%) | |||||||
Placebo | 85 ± 95 | 67 ± 70 | 62 ± 62 | 58 ± 51 | 55 ± 45 | 0.61 | 0.74 |
Paricalcitol | 92 ± 96 | 71 ± 65 | 67 ± 58 | 66 ± 55 | 63 ± 50 | 0.63 | |
u-AQP2 (ng/hr) | |||||||
Placebo | 99 ± 37 | 71 ± 29 | 77 ± 34 | 80 ± 37 | 87 ± 51 | 0.16 | 0.67 |
Paricalcitol | 100 ± 35 | 71 ± 30 | 74 ± 29 | 75 ± 32 | 75 ± 31 | 0.03 | |
u-ENaC γ (ng/hr) | |||||||
Placebo | 9.6 ± 7.7 | - | 8.8 ± 7.8 | - | 9.8 ± 9.0 | 0.92 | 0.32 |
Paricalcitol | 10.3 ± 5.3 | - | 8.2 ± 2.3 | - | 8.8 ± 3.7 | 0.21 | |